 AIM ImmunoTech Inc NYSEAMERICAN:AIM announced Wednesday that its subsidiary NV Hemispherx Biopharma Europe has received formal notification from the European Commission approving the companys Orphan Medicinal Product Application for Ampligen as a treatment for pancreatic cancer. The company noted that medications designated as Orphan products by the European Medicines Agency EMA, once commercially approved in the European Union EU, receive benefits including up to 10 years of protection from market competition from similar medicines with similar active components and indication-for-use that are not shown to be clinically superior. 